Abbott India Ltd
ABBOTINDIA NSE
Abbott India Ltd
HealthcareNSE: ABBOTINDIA BSE: 500488 Pharmaceuticals
Key Fundamentals
MidcapPharmaceuticalsHealthcareMarket Cap
₹59,296 Cr
Volatility
Moderate
P/E Ratio
38.11
EBITDA
₹2,180 Cr
Return on Equity
32.51%
Debt to Equity
0.04
Book Value
₹2,246.68
EPS
₹583.05
52W High
₹34,060
52W Low
₹25,150
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Abbott India Ltd insights
31 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
3- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 34.9%
- Company has been maintaining a healthy dividend payout of 77.9%
Weaknesses
2- Stock is trading at 12.4 times its book value
- The company has delivered a poor sales growth of 9.96% over past five years.
Growth Rate
Revenue Growth
7.97% ↗
Net Income Growth
9.73% ↗
Cash Flow Change
30.38% ↗
ROE
-2.69% ↘
ROCE
-0.52% ↘
EBITDA Margin (Avg.)
2.51% ↘
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 3d agoAI opinion · based on fundamentals
Risk medium
Abbott India Ltd is a debt-free healthcare company with a market cap of ₹59,147 Cr, trading at a PE of 38.1x and delivering a consistent ROE of ~34% over three years. The stock has underperformed over the past year with a -16% return despite steady single-digit revenue growth of 8-10% and double-digit profit compounding of 17-18% over 3-5 year periods.
Bull Case 7
- Virtually debt-free balance sheet provides financial resilience and flexibility for future investments
- Consistent ROE of 34-35% over 3 and 5-year periods indicates highly efficient capital allocation
- Compounded profit growth of 18% over 3 years and 17% over 5 years demonstrates strong earnings momentum
- Healthy dividend payout ratio of 77.9% with a current dividend yield of 2.36%, attractive for income-oriented investors in the pharma space
- Long-term stock CAGR of 19% over 10 years reflects sustained wealth creation track record
- Compounded profit growth of 20% over 10 years significantly outpaces sales growth of 10%, showing consistent margin expansion
- TTM profit growth of 9% continues to outpace TTM sales growth of 8%, indicating ongoing operational efficiency improvements
Bear Case 8
- Stock trades at 12.4x price-to-book value, a steep premium that leaves limited margin of safety
- PE ratio of 38.1x is elevated relative to broader market multiples, pricing in significant future growth expectations
- Sales growth has been modest at ~10% CAGR over 5 years, suggesting limited top-line acceleration in a competitive Indian pharma market
- Stock has delivered -16% return over the past 1 year, significantly underperforming the broader market
- TTM revenue growth of only 8% shows a deceleration from the 10% 5-year and 10-year compounded sales growth rates
- 3-year stock CAGR of only 5% suggests the market has been re-rating the stock downward despite steady fundamentals
- High dividend payout of 77.9% may constrain reinvestment capacity needed to accelerate growth beyond single digits
- Gap between profit growth (18% 3-year) and sales growth (9% 3-year) may narrow as margin expansion potential reaches its limits
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 1d ago Positives 1
- Strong FY26 revenue growth Jul 20
Abbott India reported FY 2025-26 revenue of ₹6,929 Crores, up 8.1% YoY. The Board recommended a total dividend of ₹656 per share, reflecting healthy cash generation.
Neutral 2
- FY26 annual report shared Jul 20
Abbott India shared the web-link for its FY26 Annual Report on BSE and company website.
- BRSR filed for FY 2025-26 Jul 20
Abbott India filed its Business Responsibility and Sustainability Report for FY 2025-26, disclosing ESG metrics and sustainability initiatives.
TL;DR: Abbott India delivered steady 8.1% revenue growth in FY26 to ₹6,929 Crores with a generous ₹656 per share dividend, signaling consistent execution. No material headwinds emerged in recent news flow. The company remains a defensive compounder in Indian pharma, and the trend appears stable with no red flags on the horizon.
Quarterly Results
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,343 | 1,479 | 1,494 | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 |
| Expenses | 1,063 | 1,124 | 1,113 | 1,049 | 1,109 | 1,167 | 1,194 | 1,178 | 1,176 | 1,293 | 1,255 | 1,261 | 1,229 |
| Operating Profit | 280 | 355 | 381 | 388 | 330 | 391 | 439 | 436 | 429 | 446 | 502 | 463 | 481 |
| OPM % | 21% | 24% | 25% | 27% | 23% | 25% | 27% | 27% | 27% | 26% | 29% | 27% | 28% |
| Other Income | 50 | 56 | 56 | 56 | 81 | 67 | 60 | 72 | 76 | 73 | 70 | 70 | 76 |
| Interest | 4 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 4 | 6 | 8 | 5 | 6 |
| Depreciation | 17 | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 | 19 | 19 |
| PBT | 308 | 390 | 415 | 422 | 390 | 437 | 479 | 488 | 483 | 493 | 546 | 509 | 531 |
| Tax % | 25% | 26% | 25% | 26% | 26% | 25% | 25% | 26% | 24% | 26% | 24% | 26% | 26% |
| Net Profit | 231 | 290 | 313 | 311 | 287 | 328 | 359 | 361 | 367 | 366 | 415 | 376 | 395 |
| EPS in Rs | 109 | 137 | 147 | 146 | 135 | 154 | 169 | 170 | 173 | 172 | 195 | 177 | 186 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,289 | 2,614 | 2,903 | 3,298 | 3,679 | 4,093 | 4,310 | 4,919 | 5,349 | 5,849 | 6,409 | 6,929 |
| Expenses | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,336 | 3,388 | 3,832 | 4,143 | 4,396 | 4,714 | 5,037 |
| Operating Profit | 312 | 365 | 398 | 525 | 605 | 757 | 922 | 1,088 | 1,206 | 1,453 | 1,695 | 1,892 |
| OPM % | 14% | 14% | 14% | 16% | 16% | 18% | 21% | 22% | 23% | 25% | 26% | 27% |
| Other Income | 48 | 50 | 57 | 117 | 113 | 114 | 81 | 77 | 154 | 248 | 275 | 288 |
| Interest | 0 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 11 | 25 |
| Depreciation | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 | 76 |
| PBT | 344 | 398 | 436 | 621 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 | 2,079 |
| Tax % | 34% | 36% | 37% | 35% | 36% | 26% | 25% | 26% | 25% | 26% | 25% | 25% |
| Net Profit | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,552 |
| EPS in Rs | 108 | 120 | 130 | 189 | 212 | 279 | 325 | 376 | 447 | 565 | 666 | 730 |
| Div. Payout % | 29% | 29% | 31% | 29% | 31% | 90% | 85% | 73% | 73% | 73% | 71% | 90% |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 | 4,212 | 4,753 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 175 | 153 | 152 | 113 | 83 | 197 | 172 |
| Other Liabilities | 436 | 421 | 679 | 723 | 932 | 940 | 1,086 | 1,253 | 1,254 | 1,411 | 1,487 | 1,556 |
| Total Liabilities | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 6,502 |
| Fixed Assets | 96 | 108 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 | 336 | 331 |
| CWIP | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 | 18 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,952 | 4,315 | 4,958 | 5,563 | 6,165 |
| Total Assets | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 6,502 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 215 | 249 | 307 | 153 | 499 | 626 | 727 | 948 | 893 | 1,213 | 1,012 | 1,319 |
| Investing | -187 | -77 | -155 | -215 | -257 | -401 | -72 | -396 | -148 | -416 | 182 | -371 |
| Financing | -58 | -80 | -90 | -102 | -143 | -217 | -582 | -637 | -639 | -745 | -925 | -1,066 |
| Net Cash Flow | -30 | 91 | 62 | -165 | 99 | 8 | 73 | -86 | 107 | 52 | 269 | -118 |
| Free Cash Flow | 199 | 226 | 287 | 180 | 504 | 611 | 704 | 904 | 860 | 1,165 | 960 | 1,307 |
| CFO/OP | 106 | 109 | 117 | 68 | 125 | 113 | 104 | 114 | 102 | 111 | 86 | 98 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 21 | 20 | 22 | 29 | 27 | 28 | 21 | 21 | 22 | 20 | 22 | 19 |
| Inventory Days | 107 | 91 | 107 | 112 | 106 | 83 | 110 | 94 | 80 | 70 | 92 | 94 |
| Days Payable | 54 | 56 | 101 | 92 | 116 | 104 | 116 | 122 | 109 | 114 | 110 | 109 |
| Cash Conversion Cycle | 74 | 54 | 28 | 49 | 17 | 8 | 14 | -6 | -8 | -24 | 3 | 3 |
| Working Capital Days | 30 | 32 | 21 | 63 | 22 | 10 | 4 | -7 | -8 | -14 | 99 | 2 |
| ROCE % | 40% | 38% | 34% | 41% | 37% | 35% | 35% | 38% | 41% | 46% | 46% | 45% |
Documents
3
Board Meeting Outcome for Outcome Of Board Meeting
5h - FY26 audited results approved; final dividend Rs525 and special dividend Rs131 per share, record date July 24. 5h - FY26 audited results approved; final dividend Rs525 and special dividend Rs131 per share, record date July 24.
4
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Abbott India says it was not a large corporate as of March 31, 2026; outstanding borrowing nil. 30 Apr - Abbott India says it was not a large corporate as of March 31, 2026; outstanding borrowing nil.
5
Board Meeting Intimation for Considering Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026, Along With The Audit Report Of The Statutory Auditors Thereon And To Recommend Final Dividend For The Financial Year Ended March 31, 2026.
30 Apr - Board meets May 11, 2026 to approve FY26 audited results, financial statements, and final dividend. 30 Apr - Board meets May 11, 2026 to approve FY26 audited results, financial statements, and final dividend.
Frequently Asked Questions about Abbott India Ltd
What does Abbott India Ltd do?
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.[1] It was established in 1944.[2]
Where is Abbott India Ltd (ABBOTINDIA) listed?
Abbott India Ltd is listed on the Indian stock exchanges. It is listed on NSE: ABBOTINDIA and BSE: 500488. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Abbott India Ltd belong to?
Abbott India Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Abbott India Ltd?
Abbott India Ltd has a market capitalisation of approximately ₹59296.18 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Abbott India Ltd?
The Price-to-Earnings (PE) ratio of Abbott India Ltd is 38.11. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Abbott India Ltd?
Over the past 52 weeks, Abbott India Ltd has traded between a low of ₹25,150 and a high of ₹34,060. This range helps investors understand the stock's price volatility and recent trading levels.
Does Abbott India Ltd pay dividends?
Yes, Abbott India Ltd has a dividend yield of 2.36%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Abbott India Ltd?
Abbott India Ltd has a Return on Equity (ROE) of 32.51%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Abbott India Ltd on Tapetide?
On Tapetide, you can view Abbott India Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.[1] It was established in 1944.[2]
Website abbott.co.in
CEO Mr. Kartik Rajendran
Employees 3,659
Listed 2010-01-08
Face Value ₹ 10
Issued Size 2,12,49,302